Latest Watson CEO Brief Rips Motive For FTC Subpoena

The Federal Trade Commission's bid to force Watson Pharmaceuticals Inc. CEO Paul M. Bisaro to testify in a competition probe into a patent settlement over the narcolepsy treatment Provigil is an...

Already a subscriber? Click here to view full article